Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
Cybin Inc. operates commercially as Helus Pharma and reports developments as a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists for depression, anxiety, and other mental health conditions. Company updates commonly address HLP003 in major depressive disorder, HLP004 in generalized anxiety disorder, investigational 5-HT receptor-focused compounds, clinical-research collaborations, regulatory-policy commentary, and scientific or medical leadership additions.
News about the company also covers public-company finance and corporate structure, including common-share offerings, pre-funded warrants, at-the-market equity programs, exchange-listing changes, conference presentations, quarterly financial results, and governance transitions tied to its development-stage pharmaceutical operations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cybin Inc. has launched EMBARK Open Access (EMBARK OA), a free online training course for psychedelic facilitation aimed at healthcare professionals.
This initiative is the first of its kind, promoting ethical psychological support and accessibility in psychedelic-assisted therapy. Participants can earn a Record of Completion, potentially leading to future training programs and involvement in Cybin-sponsored clinical studies.
Cybin's mission is to enhance mental healthcare through innovative psychedelic treatments, supported by expert faculty who created engaging training modules.
CEO Doug Drysdale emphasized their commitment to making training accessible, addressing the financial barriers present in existing programs.